{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:34:54Z","timestamp":1792146894759,"version":"4.4.0"},"reference-count":111,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1097\/ppo.0b013e31815a9618","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T08:36:50Z","timestamp":1209890210000},"page":"384-391","source":"Crossref","is-referenced-by-count":8,"title":["Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia, and Mast Cell Disease"],"prefix":"10.1097","volume":"13","author":[{"given":"Animesh","family":"Pardanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210203","first-page":"963","article-title":"Eosinophilia detected by automated blood cell counting in ambulatory North American outpatients: incidence and clinical significance.","volume":"121","author":"Brigden","year":"1997","journal-title":"Arch Pathol Lab Med"},{"key":"R2-8-20210203","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2006.06038.x","article-title":"Eosinophilia: secondary, clonal and idiopathic.","volume":"133","author":"Tefferi","year":"2006","journal-title":"Br J Haematol"},{"key":"R3-8-20210203","first-page":"16","article-title":"Detection of eosinophil differentiation factor and its relationship to eosinophilia in Mesocestoides corti-infected mice.","volume":"14","author":"Strath","year":"1986","journal-title":"Exp Hematol"},{"key":"R4-8-20210203","first-page":"1152","article-title":"In vivo changes of hemopoietic progenitors and the expression of the interleukin 5 gene in eosinophilic mice infected with Toxocara canis.","volume":"18","author":"Yamaguchi","year":"1990","journal-title":"Exp Hematol"},{"key":"R5-8-20210203","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1172\/JCI115166","article-title":"Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma.","volume":"87","author":"Hamid","year":"1991","journal-title":"J Clin Invest"},{"key":"R6-8-20210203","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00000478-198307000-00005","article-title":"Systemic mastocytosis. Extracutaneous manifestations.","volume":"7","author":"Brunning","year":"1983","journal-title":"Am J Surg Pathol"},{"key":"R7-8-20210203","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S0046-8177(85)80252-5","article-title":"Bone marrow findings in systemic mastocytosis.","volume":"16","author":"Horny","year":"1985","journal-title":"Hum Pathol"},{"key":"R8-8-20210203","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1309\/Q2WJ-46CL-YRFT-M5JF","article-title":"Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease.","volume":"116","author":"Stevens","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"R9-8-20210203","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.V91.8.2731.2731_2731_2736","article-title":"Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications.","volume":"91","author":"Escribano","year":"1998","journal-title":"Blood"},{"key":"R10-8-20210203","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood.V98.13.3784","article-title":"Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells.","volume":"98","author":"Schernthaner","year":"2001","journal-title":"Blood"},{"key":"R11-8-20210203","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.leukres.2003.10.035","article-title":"Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients.","volume":"28","author":"Pardanani","year":"2004","journal-title":"Leuk Res"},{"key":"R12-8-20210203","first-page":"29","article-title":"World Health Organization Classification of Tumours: Tumours of the Haematopoietic and Lymphoid Tissues.","author":"Bain","year":"2001"},{"key":"R13-8-20210203","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia.","volume":"341","author":"Simon","year":"1999","journal-title":"N Engl J Med"},{"key":"R14-8-20210203","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ajh.1157","article-title":"Diverse clinical outcomes of eosinophilic patients with T-cell receptor gene rearrangements: the emerging diagnostic importance of molecular genetics testing.","volume":"68","author":"Butterfield","year":"2001","journal-title":"Am J Hematol"},{"key":"R15-8-20210203","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood.V93.5.1651","article-title":"Clonality of isolated eosinophils in the hypereosinophilic syndrome.","volume":"93","author":"Chang","year":"1999","journal-title":"Blood"},{"key":"R16-8-20210203","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.20088","article-title":"Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.","volume":"77","author":"Bain","year":"2004","journal-title":"Am J Hematol"},{"key":"R17-8-20210203","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-97-1-78","article-title":"NIH conference. The idiopathic hypereosinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations.","volume":"97","author":"Fauci","year":"1982","journal-title":"Ann Intern Med"},{"key":"R18-8-20210203","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0002-9149(83)90131-5","article-title":"Noncardiovascular findings associated with heart disease in the idiopathic hypereosinophilic syndrome.","volume":"52","author":"Harley","year":"1983","journal-title":"Am J Cardiol"},{"key":"R19-8-20210203","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/0003-4819-102-1-109","article-title":"Neurologic dysfunction in the idiopathic hypereosinophilic syndrome.","volume":"102","author":"Moore","year":"1985","journal-title":"Ann Intern Med"},{"key":"R20-8-20210203","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/j.1523-1755.2005.00278.x","article-title":"Thrombotic microangiopathy associated with the hypereosinophilic syndrome.","volume":"67","author":"Liapis","year":"2005","journal-title":"Kidney Int"},{"key":"R21-8-20210203","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood.V83.10.2759.2759","article-title":"The idiopathic hypereosinophilic syndrome.","volume":"83","author":"Weller","year":"1994","journal-title":"Blood"},{"key":"R22-8-20210203","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0002-9149(00)00841-9","article-title":"Clinical and echocardiographic features of hypereosinophilic syndromes.","volume":"86","author":"Ommen","year":"2000","journal-title":"Am J Cardiol"},{"key":"R23-8-20210203","first-page":"253","article-title":"Prognostic factors of hypereosinophilic syndrome: study of 40 cases.","volume":"140","author":"Lefebvre","year":"1989","journal-title":"Ann Med Interne (Paris)"},{"key":"R24-8-20210203","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/jama.1982.03320320054032","article-title":"Recurrent incapacitating mucosal ulcerations: a prodrome of the hypereosinophilic syndrome.","volume":"247","author":"Leiferman","year":"1982","journal-title":"JAMA"},{"key":"R25-8-20210203","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2169\/internalmedicine.39.350","article-title":"Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder.","volume":"39","author":"Sato","year":"2000","journal-title":"Intern Med"},{"key":"R27-8-20210203","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-89-2-167","article-title":"Therapy of the hypereosinophilic syndrome.","volume":"89","author":"Parrillo","year":"1978","journal-title":"Ann Intern Med"},{"key":"R28-8-20210203","doi-asserted-by":"crossref","first-page":"648","DOI":"10.7326\/0003-4819-121-9-199411010-00003","article-title":"Interferon-\u03b1 treatment of six patients with the idiopathic hypereosinophilic syndrome.","volume":"121","author":"Butterfield","year":"1994","journal-title":"Ann Intern Med"},{"key":"R29-8-20210203","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/000331970205300414","article-title":"Favorable response to high-dose interferon-\u03b1 in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy\u2014case report and literature review.","volume":"53","author":"Baratta","year":"2002","journal-title":"Angiology"},{"key":"R30-8-20210203","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1346-8138.2000.tb02131.x","article-title":"Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review.","volume":"27","author":"Yoon","year":"2000","journal-title":"J Dermatol"},{"key":"R31-8-20210203","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002770050434","article-title":"Interferon-\u03b1 in the idiopathic hypereosinophilic syndrome: consideration of five cases.","volume":"77","author":"Ceretelli","year":"1998","journal-title":"Ann Hematol"},{"key":"R32-8-20210203","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"key":"R33-8-20210203","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1046\/j.1365-2141.2003.04801.x","article-title":"Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome.","volume":"124","author":"Sefcick","year":"2004","journal-title":"Br J Haematol"},{"key":"R34-8-20210203","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2004.05206.x","article-title":"Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report.","volume":"127","author":"Pitini","year":"2004","journal-title":"Br J Haematol"},{"key":"R35-8-20210203","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0002-9343(03)00475-3","article-title":"Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib.","volume":"115","author":"Koury","year":"2003","journal-title":"Am J Med"},{"key":"R36-8-20210203","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.","volume":"349","author":"Plotz","year":"2003","journal-title":"N Engl J Med"},{"key":"R37-8-20210203","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"R38-8-20210203","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2004.08.027","article-title":"Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.","volume":"114","author":"Kim","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R39-8-20210203","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/sj.leu.2404154","article-title":"Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.","volume":"20","author":"Score","year":"2006","journal-title":"Leukemia"},{"key":"R40-8-20210203","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/hmg\/11.12.1391","article-title":"The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.","volume":"11","author":"Baxter","year":"2002","journal-title":"Hum Mol Genet"},{"key":"R41-8-20210203","doi-asserted-by":"crossref","DOI":"10.1002\/gcc.20359","article-title":"Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.","author":"Walz","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"R42-8-20210203","first-page":"817","article-title":"A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia.","volume":"91","author":"Bacher","year":"2006","journal-title":"Haematologica"},{"key":"R43-8-20210203","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leuk Res"},{"key":"R44-8-20210203","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia.","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"key":"R45-8-20210203","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"R46-8-20210203","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor \u03b2 to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"key":"R47-8-20210203","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1182\/blood.V90.11.4271","article-title":"Fusion of the platelet-derived growth factor receptor \u03b2 to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution.","volume":"90","author":"Abe","year":"1997","journal-title":"Blood"},{"key":"R48-8-20210203","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.leu.2403548","article-title":"KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).","volume":"19","author":"Levine","year":"2005","journal-title":"Leukemia"},{"key":"R49-8-20210203","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1158\/0008-5472.CAN-04-0144","article-title":"NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.","volume":"64","author":"Vizmanos","year":"2004","journal-title":"Cancer Res"},{"key":"R50-8-20210203","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1158\/0008-5472.CAN-03-4026","article-title":"HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17) (q33;p11. 2).","volume":"64","author":"Morerio","year":"2004","journal-title":"Cancer Res"},{"key":"R51-8-20210203","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1182\/blood-2003-04-1150","article-title":"Cloning of the t(1;5) (q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib.","volume":"102","author":"Wilkinson","year":"2003","journal-title":"Blood"},{"key":"R52-8-20210203","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1182\/blood.V98.8.2518","article-title":"Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia.","volume":"98","author":"Magnusson","year":"2001","journal-title":"Blood"},{"key":"R53-8-20210203","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1182\/blood.V91.12.4419","article-title":"Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor \u03b2 receptor (PDGF\u03b2R) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2).","volume":"91","author":"Ross","year":"1998","journal-title":"Blood"},{"key":"R54-8-20210203","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1182\/blood.V97.12.3910","article-title":"H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor \u03b2 gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22).","volume":"97","author":"Schwaller","year":"2001","journal-title":"Blood"},{"key":"R55-8-20210203","doi-asserted-by":"crossref","first-page":"7216","DOI":"10.1158\/0008-5472.CAN-04-2005","article-title":"p53-binding protein 1 is fused to the platelet-derived growth factor receptor \u03b2 in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder.","volume":"64","author":"Grand","year":"2004","journal-title":"Cancer Res"},{"key":"R56-8-20210203","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor \u03b2.","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"R57-8-20210203","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.10980","article-title":"Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor \u03b2 gene.","volume":"92","author":"Walz","year":"2007","journal-title":"Haematologica"},{"key":"R58-8-20210203","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000046639","article-title":"The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1.","volume":"107","author":"Macdonald","year":"2002","journal-title":"Acta Haematol"},{"key":"R59-8-20210203","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1182\/blood.V90.8.3136","article-title":"Molecular characterization of the t(8;13)(p11;q12) translocation associated with an atypical myeloproliferative disorder: evidence for three discrete loci involved in myeloid leukemias on 8p11.","volume":"90","author":"Still","year":"1997","journal-title":"Blood"},{"key":"R60-8-20210203","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ng0198-84","article-title":"FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia\/lymphoma syndrome.","volume":"18","author":"Xiao","year":"1998","journal-title":"Nat Genet"},{"key":"R61-8-20210203","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/hmg\/7.4.637","article-title":"The t(8;13)(p11;q11\u201312) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP.","volume":"7","author":"Smedley","year":"1998","journal-title":"Hum Mol Genet"},{"key":"R62-8-20210203","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1073\/pnas.95.10.5712","article-title":"Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13).","volume":"95","author":"Popovici","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"R63-8-20210203","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood.V92.5.1735","article-title":"Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome.","volume":"92","author":"Reiter","year":"1998","journal-title":"Blood"},{"key":"R64-8-20210203","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.leukres.2006.10.005","article-title":"\u2018Idiopathic' eosinophilia with an occult T-cell clone: prevalence and clinical course.","volume":"31","author":"Vaklavas","year":"2007","journal-title":"Leuk Res"},{"key":"R65-8-20210203","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal.","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"R66-8-20210203","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.iac.2006.05.002","article-title":"Diagnostic evaluation and classification of mastocytosis.","volume":"26","author":"Valent","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"R67-8-20210203","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000048188","article-title":"Mastocytosis: mediator-related signs and symptoms.","volume":"127","author":"Castells","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"R69-8-20210203","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/jcp.2003.014860","article-title":"Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.","volume":"57","author":"Horny","year":"2004","journal-title":"J Clin Pathol"},{"key":"R70-8-20210203","article-title":"Mastocytosis and the Mast Cell.","author":"Sagher","year":"1967"},{"key":"R71-8-20210203","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2559.1979.tb03017.x","article-title":"Mast cells and mast cell neoplasia: a review.","volume":"3","author":"Lennert","year":"1979","journal-title":"Histopathology"},{"key":"R72-8-20210203","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2141.1990.tb07870.x","article-title":"Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders.","volume":"76","author":"Horny","year":"1990","journal-title":"Br J Haematol"},{"key":"R73-8-20210203","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19880901)62:5<965::AID-CNCR2820620520>3.0.CO;2-M","article-title":"Significance of systemic mast cell disease with associated hematologic disorders.","volume":"62","author":"Travis","year":"1988","journal-title":"Cancer"},{"key":"R74-8-20210203","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/10428190009058500","article-title":"Clinical and biologic diversity of leukemias occurring in patients with mastocytosis.","volume":"37","author":"Sperr","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"R76-8-20210203","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/00000478-199809000-00013","article-title":"Diagnostic value of immunostaining for tryptase in patients with mastocytosis.","volume":"22","author":"Horny","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"R77-8-20210203","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000048180","article-title":"Histopathological and immunohistochemical aspects of mastocytosis.","volume":"127","author":"Horny","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"R78-8-20210203","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1053\/hupa.2001.24319","article-title":"Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117\/Kit, and bcl-x(L).","volume":"32","author":"Jordan","year":"2001","journal-title":"Hum Pathol"},{"key":"R79-8-20210203","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/01.pas.0000138181.89743.7b","article-title":"CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens.","volume":"28","author":"Sotlar","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"R80-8-20210203","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.iac.2006.05.008","article-title":"Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease.","volume":"26","author":"Escribano","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"R81-8-20210203","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","article-title":"Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis.","volume":"316","author":"Schwartz","year":"1987","journal-title":"N Engl J Med"},{"key":"R82-8-20210203","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2353\/jmoldx.2006.060022","article-title":"Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.","volume":"8","author":"Akin","year":"2006","journal-title":"J Mol Diagn"},{"key":"R83-8-20210203","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0145-2126(02)00041-3","article-title":"Detection of c-kit point mutation Asp-816 \u2192 Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia.","volume":"26","author":"Sotlar","year":"2002","journal-title":"Leuk Res"},{"key":"R84-8-20210203","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0145-2126(03)00065-1","article-title":"Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia.","volume":"27","author":"Pardanani","year":"2003","journal-title":"Leuk Res"},{"key":"R85-8-20210203","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2002-01-0203","article-title":"Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene.","volume":"100","author":"Yavuz","year":"2002","journal-title":"Blood"},{"key":"R86-8-20210203","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9440(10)63870-9","article-title":"One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes.","volume":"162","author":"Sotlar","year":"2003","journal-title":"Am J Pathol"},{"key":"R87-8-20210203","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow haematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"R88-8-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrfmmm.2004.08.015","article-title":"Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis.","volume":"572","author":"Lawley","year":"2005","journal-title":"Mutat Res"},{"key":"R89-8-20210203","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0952-8180(90)90063-9","article-title":"Urticaria pigmentosa: an anesthetic challenge.","volume":"2","author":"Greenblatt","year":"1990","journal-title":"J Clin Anesth"},{"key":"R90-8-20210203","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/bja\/65.2.254","article-title":"Anaesthetic management of systemic mastocytosis.","volume":"65","author":"Lerno","year":"1990","journal-title":"Br J Anaesth"},{"key":"R91-8-20210203","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00000658-198305000-00002","article-title":"Hazards in operative management of patients with systemic mastocytosis.","volume":"197","author":"Scott","year":"1983","journal-title":"Ann Surg"},{"key":"R92-8-20210203","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00000542-197304000-00018","article-title":"Anesthetic considerations in mastocytosis.","volume":"38","author":"Rosenbaum","year":"1973","journal-title":"Anesthesiology"},{"key":"R93-8-20210203","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0091-6749(83)90098-2","article-title":"Intervention with epinephrine in hypotension associated with mastocytosis.","volume":"71","author":"Turk","year":"1983","journal-title":"J Allergy Clin Immunol"},{"key":"R94-8-20210203","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-\u03b1: results of a multicentre phase II trial on 20 patients.","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"key":"R95-8-20210203","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis.","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N Engl J Med"},{"key":"R96-8-20210203","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1365-2133.1998.02131.x","article-title":"Response of severe systemic mastocytosis to interferon alpha.","volume":"138","author":"Butterfield","year":"1998","journal-title":"Br J Dermatol"},{"key":"R97-8-20210203","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2133.1995.tb02499.x","article-title":"Treatment of urticaria pigmentosa using interferon \u03b1.","volume":"133","author":"Kolde","year":"1995","journal-title":"Br J Dermatol"},{"key":"R98-8-20210203","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/rheumatology\/35.9.898","article-title":"Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon \u03b1-2B.","volume":"35","author":"Lehmann","year":"1996","journal-title":"Br J Rheumatol"},{"key":"R99-8-20210203","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00663015","article-title":"Successful treatment of osteoporosis in systemic mastocytosis with interferon \u03b1-2b.","volume":"72","author":"Weide","year":"1996","journal-title":"Ann Hematol"},{"key":"R100-8-20210203","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.leukres.2004.05.003","article-title":"Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case.","volume":"29","author":"Butterfield","year":"2005","journal-title":"Leuk Res"},{"key":"R101-8-20210203","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2169\/internalmedicine.37.484","article-title":"Systemic mastocytosis with extensive polypoid lesions in the intestines; successful treatment with interferon-\u03b1.","volume":"37","author":"Takasaki","year":"1998","journal-title":"Intern Med"},{"key":"R102-8-20210203","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","article-title":"Response to therapy with interferon \u03b1-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature.","volume":"28","author":"Hauswirth","year":"2004","journal-title":"Leuk Res"},{"key":"R103-8-20210203","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/0190-9622(95)91545-1","article-title":"Systemic mastocytosis associated with chronic myelomonocytic leukemia: clinical features and response to interferon alfa therapy.","volume":"32","author":"Petit","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"R104-8-20210203","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s002770050604","article-title":"IFN\u03b1 treatment in systemic mastocytosis.","volume":"78","author":"Lehmann","year":"1999","journal-title":"Ann Hematol"},{"key":"R105-8-20210203","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/j.1365-2133.1996.tb07977.x","article-title":"Long-term effect of interferon \u03b1 treatment in mastocytosis.[comment].","volume":"134","author":"Lippert","year":"1996","journal-title":"Br J Dermatol"},{"key":"R106-8-20210203","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000204898","article-title":"Anaphylactic-like syndrome in systemic mastocytosis treated with \u03b1-2-interferon.","volume":"85","author":"Pardini","year":"1991","journal-title":"Acta Haematol"},{"key":"R107-8-20210203","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine.","volume":"344","author":"Tefferi","year":"2001","journal-title":"N Engl J Med"},{"key":"R108-8-20210203","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(03)00185-1","article-title":"Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine.","volume":"28","author":"Pardanani","year":"2004","journal-title":"Leuk Res"},{"key":"R109-8-20210203","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0145-2126(02)00073-5","article-title":"Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis: report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma.","volume":"26","author":"Escribano","year":"2002","journal-title":"Leuk Res"},{"key":"R110-8-20210203","first-page":"658","article-title":"\u201cSmoldering systemic mastocytosis\u201d: successful therapy with cladribine.","volume":"55","author":"Schleyer","year":"2004","journal-title":"Hautarzt"},{"key":"R111-8-20210203","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis.","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"R112-8-20210203","doi-asserted-by":"crossref","first-page":"190a","DOI":"10.1182\/blood.V104.11.661.661","article-title":"Efficacy and safety of cladribine in adult systemic mastocytosis.","volume":"104","author":"Lortholary","year":"2004","journal-title":"Blood"},{"key":"R113-8-20210203","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease.","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"R114-8-20210203","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.leukres.2003.09.001","article-title":"Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis.","volume":"28","author":"Musto","year":"2004","journal-title":"Leuk Res"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0b013e31815a9618","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:39:11Z","timestamp":1786034351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00130404-200711000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":111,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0b013e31815a9618","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}